Literature DB >> 27183553

Reduction of Diabetic Macular Edema in the Untreated Fellow Eye Following Intravitreal Injection of Aflibercept.

Charles M Calvo, Jayanth Sridhar, Abtin Shahlaee, Allen C Ho.   

Abstract

A 59-year-old patient with bilateral worsening diabetic macular edema received intravitreal injection of aflibercept (Eylea; Regeneron, Tarrytown, NY) to the left eye only. On 1-month follow-up, there was noted bilateral improvement of visual acuity and diabetic macular edema on spectral-domain optical coherence tomography imaging, reflecting bilateral effect of unilateral treatment with aflibercept. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:474-476.]. Copyright 2016, SLACK Incorporated.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27183553     DOI： 10.3928/23258160-20160419-12

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN： 2325-8160            Impact factor:   1.300


  5 in total

1.  Predictive Assessment of Quantitative Ultra-Widefield Angiographic Features for Future Need for Anti-VEGF Therapy in Diabetic Eye Disease.

Authors:  Alice C Jiang; Duriye Damla Sevgi; Christopher Mugnaini; Jon Whitney; Sunil K Srivastava; Katherine E Talcott; Ming Hu; Jamie L Reese; Justis P Ehlers
Journal:  J Pers Med       Date:  2022-04-10

2.  Effect of intravitreal ranibizumab on the ocular circulation of the untreated fellow eye.

Authors:  Masahiko Sugimoto; Takayasu Nunome; Rie Sakamoto; Maki Kobayashi; Mineo Kondo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-28       Impact factor: 3.117

3.  Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema.

Authors:  Sameh Mosaad Fouda; Ahmed M Bahgat
Journal:  Clin Ophthalmol       Date:  2017-03-23

4.  Therapeutic Effect of Anti-VEGF for Age-Related Macular Degeneration in the Untreated Fellow Eye.

Authors:  Hacer Isildak; Stephen G Schwartz; Harry W Flynn
Journal:  Case Rep Ophthalmol Med       Date:  2018-04-24

5.  Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease.

Authors:  Rachael Ann O'Neill; Patrick Gallagher; Tricia Douglas; Julie-Anne Little; Alexander Peter Maxwell; Giuliana Silvestri; Gareth McKay
Journal:  BMC Nephrol       Date:  2019-12-26       Impact factor: 2.388
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.